Erika Martinelli, MD, PhD

Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer

Background Trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) was compared with TAS-102 monotherapy in a randomized, open-label, phase 2 trial, and produced a stati...

T. Troiani ;

P. Incoronato ;

Ralph J. Napolitano Jr., DPM, CWSP, FACFAS;

V. Nacca ;

F. Paragliola ;

G. Suarato ;

A. Nicastro ;

A. Perrone ;

Erika Martinelli , MD, PhD;

G. Arrichiello ;

06/27/2022

Challenging Cases in Rectal Cancer

Erika Martinelli , MD, PhD;

Andre JL D'Hoore , MD, PhD, FACS;

07/07/2023

BRAF Mutant Tumors: Strategy and New Data

Erika Martinelli , MD, PhD;

07/07/2023

Videos

Upcoming Advancements in the Treatment of BRAF-Mutant, Metastatic Colorectal Cancer

08/23/2023

Erika Martinelli , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Erika Martinelli, MD, PhD, highlighted key upcoming advancements for the treatment of BRAF-mutant metastatic colorectal cancer.

At the 2023 World Congress on...

08/23/2023

Oncology

How to find a good mentor in Europe

Erika Martinelli , MD, PhD;

07/10/2018

Highlights of posters at ESMO GI on non-CRC

Erika Martinelli , MD, PhD;

07/10/2018

How to Build Your Career in GI Oncology?

Erika Martinelli , MD, PhD;

07/01/2021